Background. Bloodstream infections are a major cause of morbidity and mortality worldwide, with favorable clinical outcomes associated with early optimal antibiotic selection. Rapid diagnostics have become a key part in achieving this. Biofire Filmarray® was introduced at our institution for rapid blood culture (BC) identification, coupled with antimicrobial stewardship (AS) interventions. We aimed to assess the impact of this test on time to adequate antimicrobial therapy in a setting with pre-existing effective AS interventions.
Methods. An observational retrospective chart review, pre and post study was performed. We reviewed adult positive BC before and after implementation of Biofire. Outcomes were: (1) time from BC result reported to health care provider to start of adequate antimicrobial therapy,(2) time to stopping antimicrobial therapy in BC thought to be contaminants, (3) time to any change in antimicrobial therapy and (4) a composite outcome of outcomes 1 and 2. A univariate Cox proportional hazards model was performed.
Results. 326 positive BC were analyzed, 173 before and 153 after Biofire implementation. At the time of healthcare provider notification, 77 were not on adequate antimicrobials, with median time to adequate therapy of 6.98 hours. ) before and 6.1 hours. ) after implementation, P = 0.48. There were 75 BC classified as contaminants and median time to stopping antimicrobials was 48.28 , P = 0.61. Time to any change in any antimicrobial therapy was similar with a median of 13.05 , P = 0.87. Analysis of the composite outcome revealed a median of hours. (Hazard ratio 1.33, 95% confidence interval 0.96-1.84, P = 0.09).
Conclusion. Implementation of the Biofire Filmarray® did not have a statistically significant effect on our composite outcome of time to adequate therapy and time to discontinuation in the case of contaminants. Our findings suggests that when added to other effective AS surveillance and interventions, the magnitude of the clinical impact of rapid PCR diagnostics for BC identification is minimal. Methods. We performed a single-center retrospective cohort study of patients who had clinical specimens sent for universal PCR from August 2013 to April 2016. Clinical data were extracted from medical records. Odds ratios were calculated and patients testing positive/negative were compared with univariate logistic regression. Sensitivity, specificity, positive predictive value and negative predictive values were calculated by comparing the test result with a gold standard composite final clinical diagnosis determined by 3 independent reviewers based on all available clinical information.
Results. 71 tissue samples were included, of which 21(29.6%) were positive. 12 bacteria, 3 mycobacteria and 7 fungi were identified. The number of leukocytes in the gram stain (odds ratio, OR 1.57, P = 0.04) and presence of inflammation on histopathological examination (OR 5.69, P = 0.02) were found to be significantly associated with a positive result. The sensitivity, specificity, positive predictive value, and negative predictive values were 56%, 95%, 91% and 70% respectively. Management was altered in 22 patients, 9 of whom had a positive and 13 had a negative result.
Conclusion. These findings suggest that the universal PCR assay has significant clinical utility, but the yield of this test can be optimized by careful patient/specimen selection. Utility was highest in patients with microscopic evidence of inflammation by gram stain or histopathlogical examination. Specificity was high. The use of this complex, difficult to interpret, and expensive test should be limited to infectious disease physicians incorporating all available clinical information to optimize performance.
Disclosures. All authors: No reported disclosures. Background. Rapid diagnostic tests in combination with antimicrobial stewardship interventions have been shown to improve antimicrobial therapy-related outcomes in patients with blood stream infections (BSIs). The Accelerate Pheno™ System (APS) has a potential advantage over many currently approved rapid diagnostic tests in that it can quickly provide both identification and antimicrobial susceptibility (AS) information. This study aimed to explore the impact of utilization of the APS when compared with VITEK-2 on time to simulated antimicrobial stewardship service intervention (ASTEW-I) in patients with Gram-negative BSIs. Potential impact of availability of ASTEW-I based on time of day was also examined.
Impact of Accelerate Pheno System on Time to Antimicrobial Stewardship Intervention in Patients with
Methods. Consecutive patients with Gram-negative rod blood stream isolates were enrolled during a 3 month time frame (February-May 2017) . The standard of care (SOC) laboratory protocol consisted of matrix-assisted laser desorption ionization time of flight (MALDI-TOF) for pathogen identification and VITEK-2 for AS results. Antimicrobial susceptibility reporting on the electronic health record was performed once daily in the morning. The isolates that were analyzed through SOC measures were also simultaneously tested on the APS. Time to ASTEW-I was simulated utilizing AS reporting time and availability of personnel for ASTEW-I based on time of day.
Results. 27 patients with positive blood cultures for Gram-negative rods were enrolled in the study. Mean decrease in time to simulated ASTEW-I with APS was 18 hours (95% CI 11.5-24.6) for 8 hour stewardship coverage. When stewardship coverage was extended to 16 hours, the mean decrease in time to ASTEWI-I with APS was 21.4 hours (95% CI 14.3-28.5). Both time differences were found to be statistically significant (P < 0.001).
Conclusion. In a cohort of patients with Gram-negative bacteremia, when compared with SOC, ASTEW-I guided by APS significantly shortened the time to potential antimicrobial optimization. This improvement occurred even when antimicrobial stewardship support was limited to an 8 hour work day. Background. In order to detect multidrug resistant (MDR) bacteria, our laboratory routinely performs direct susceptibility (DS) testing from positive blood cultures. We conducted a prospective study to determine the accuracy, reporting time (RT), and antimicrobial stewardship impact of DS testing for Gram-negative bacilli (GNB) positive blood cultures.
Methods. From March -December 2016, first time positive blood cultures for GNB were included in the study. Broth from positive blood culture bottles was inoculated to standard media, as well as to Mueller-Hinton agar with cefoxitin (FOX), amoxicillin/ clavulanic acid (AMC), ceftriaxone (CRO), ceftazidime (CAZ), ciprofloxacin (CIP) and meropenem (MEM) disks. The CRO and CAZ were adjacent to the AMC disk, which enabled detection of zone-enhancement with extended-spectrum β-lactamase (ESBL) producing organisms. CLSI breakpoints were used to guide interpretations of the DS results. Antibiotic therapy changes, made based on verbal reporting of DS results, were recorded. In order to determine RT, the following time points were recorded: blood culture positivity, reading of DS, and reporting of standardized susceptibilities (SS).
Results. There were 105 unique, monomicrobial cultures consisting of: E. coli (N = 61), Klebsiella sp. (N = 15) , Enterobacter sp. (N = 9) , Proteus sp. (N = 5), Pseudomonas aeruginosa(N = 5), and 10 other miscellaneous GNB. RT was reduced from 38 to 22 hours, for SS and DS, respectively. For species with CLSI breakpoints (101 isolates), the major and minor errors for all antibiotics were 2% and 20%, respectively; 17% of isolates were DS-intermediate and SS-susceptible (minor error). CIP disk testing identified all resistant isolates correctly (N = 21), as did MEM (N = 7). Resistance to CRO/CAZ was correctly identified in 26/27 isolates. DS results changed antibiotic management for 23 patients. Antibiotics were narrowed for 7 patients, and treatment was expanded for 16 patients. For these patients, DS results were available 24 hours before SS.
Conclusion. DS testing is an accurate and rapid method to detect MDR GNB blood culture pathogens and facilitates the optimization of antimicrobial therapy. A relatively high rate of minor errors was detected due to DS disks testing in the intermediate zone for isolates ultimately identified as susceptible by SS.
Disclosures. All authors: No reported disclosures. Saturday, October 7, 2017: 12:30 PM Background. Previous studies have demonstrated that the methicillin-resistant Staphylococcus aureus(MRSA) nasal polymerase chain reaction (PCR) assay has a high negative predictive value for MRSA pneumonia, and that a negative result may be used to guide antibiotic de-escalation. Despite increasing use in clinical practice, limited data exist regarding the impact of nasal MRSA testing on the duration of MRSAdirected therapy and patient outcomes. This study evaluated the effect of the MRSA nasal PCR result on vancomycin days and clinical outcomes in patients treated for pneumonia with empiric vancomycin therapy.
Effect of the Methicillin-Resistant
Methods. A retrospective study of adult inpatients with an MRSA nasal PCR assay ordered between January 2015 and September 2015 was conducted. Patients with confirmed or presumed pneumonia and who were treated with empiric vancomycin therapy were included. Outcomes were compared for patients with a negative vs. a positive MRSA nasal PCR result. The primary outcome was the number of days of vancomycin therapy. Secondary outcomes included restart of vancomycin within 7 days, length of hospitalization, 30-day readmission, 30-day mortality, and predictive value of the MRSA PCR assay. Analyses were performed for the overall cohort and a propensity score-matched cohort.
Results. 324 patients were included. In the overall cohort, the median duration of vancomycin therapy was 3 (interquartile range [IQR] 2-6) days in the negative MRSA nasal PCR group (n = 282) and 6 (IQR 4-9) days in the positive nasal PCR group (n = 42), P < 0.01. In the propensity score-matched cohort, the median number of vancomycin days was 3 (IQR 2-5) and 5 (IQR 4-8.5) in the negative (n = 137) and positive (n = 39) nasal PCR groups, respectively, P < 0.01. This difference persisted in an additional analysis of only patients with no positive respiratory cultures. No significant differences were observed in any secondary outcomes. The MRSA PCR assay demonstrated a positive predictive value of 45% and a negative predictive value of 98%. Conclusion. A negative MRSA nasal PCR correlated with fewer days of vancomycin therapy without negatively impacting other clinical outcomes. The use of the MRSA nasal PCR assay may reduce the duration of MRSA-active therapy in PCRnegative patients.
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